Electromedical Products International

What Electromedical Products International does

Electromedical Products International, Inc. (EPI) is a privately held U.S. medical device company founded in 1981 by Dr. Daniel Kirsch and headquartered in Mineral Wells, Texas. It develops, manufactures, and markets the Alpha-Stim family of FDA-cleared, non-invasive neuromodulation devices, which deliver a patented waveform via mild microcurrents for cranial electrotherapy stimulation (CES) targeting anxiety and insomnia, and microcurrent electrical therapy (MET) targeting pain. EPI distributes Alpha-Stim commercially in over 50 countries (over-the-counter internationally, prescription-only in the U.S.) and holds a continuous presence on the Federal Supply Schedule since 2005, selling directly to the Department of Veterans Affairs and Department of Defense under a renewed five-year, $175M contract (Nov 2025–Oct 2030). Supporting products include AS-Trode silver electrode pads as a recurring consumable line.

The company extends its technology platform through wholly-owned subsidiary Pulvinar Neuro, acquired in March 2022, which is developing next-generation non-invasive brain stimulation including closed-loop transcranial alternating current stimulation (tACS), individualized feedback stimulation, cloud-enabled digital therapeutics, and the XCSITE-RD research device for tACS/tDCS studies. Pulvinar's closed-loop tACS device received FDA Breakthrough Device designation in December 2024 for Major Depressive Disorder, supported by an American Journal of Psychiatry–published trial (August 2024) reporting 80% of MDD patients free of clinical depression symptoms after five daily sessions. EPI's go-to-market combines enterprise field sales to federal agencies (via GSA Advantage!), data-driven physician outreach using AcuityMD's AI platform, clinical-research–led credibility with academic partners (notably UNC Chapel Hill), and multi-channel content marketing. Leadership includes CEO Tracey B. Kirsch, President Brian Burke, CSO Dr. Leah Townsend, and VP of Government Affairs Tonja Trammell, with Dr. Flavio Frohlich (UNC) chairing the Scientific Advisory Board.

Name

Electromedical Products International

Legal name

Electromedical Products International, Inc.

Website

https://epii.com

Company type

Private

Founded year

1981

Operating status

Operating

Headcount range

51–100 employees

Short description

Electromedical Products International (EPI), founded in 1981 and based in Mineral Wells, Texas, develops and manufactures the FDA-cleared Alpha-Stim line of non-invasive cranial electrotherapy and microcurrent devices for anxiety, insomnia, and pain, selling to federal agencies via the Federal Supply Schedule and commercially in 50+ countries. Through subsidiary Pulvinar Neuro, it is developing closed-loop tACS for Major Depressive Disorder under FDA Breakthrough Device designation.

Ownership category

akta.pro rank

Headquarters

HQ city

Mineral Wells

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales - Federal Government: Sales of FDA-cleared Alpha-Stim medical devices to federal agencies through Federal Supply Schedule contract. Five-year $175M contract (Nov 2025 - Oct 2030) enables streamlined procurement for VA, DoD, and authorized federal purchasers.
2. Medical Device Sales - Commercial: Alpha-Stim devices sold commercially in over 50 countries worldwide. Available over-the-counter internationally, requires prescription in the US.
3. Research Device Sales: XCSITE-RD research devices sold to researchers and research institutions for brain stimulation studies.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Electromedical Products International (EPI) develops and manufactures FDA-cleared Alpha-Stim medical devices that deliver cranial electrotherapy stimulation (CES) and microcurrent electrical therapy (MET) for the treatment of anxiety, insomnia, depression, and pain. Through its wholly-owned subsidiary Pulvinar Neuro, EPI also develops advanced non-invasive brain stimulation research solutions including the XCSITE-RD research platform and an investigational closed-loop transcranial alternating current stimulation (tACS) device for Major Depressive Disorder.

Product overview

Electromedical Products International (EPI) is a global medical device company offering a portfolio of neuromodulation therapeutics centered on its FDA-cleared Alpha-Stim brand devices. The core product line includes Alpha-Stim M (combining CES and MET for pain, anxiety, and insomnia) and Alpha-Stim AID (CES for anxiety and insomnia), supported by AS-Trode electrode accessories. Through its wholly-owned subsidiary Pulvinar Neuro, EPI is developing next-generation brain stimulation technology including XCSITE-RD (research platform for tACS/tDCS) and an investigational Closed-Loop tACS device for Major Depressive Disorder. The portfolio spans consumer/clinical devices and research tools, all based on non-invasive electrical neuromodulation technology.

Differentiator

Problem solved

Functional benefit

Brands

• Alpha-Stim: FDA-cleared medical device brand offering cranial electrotherapy stimulation (CES) for anxiety and insomnia, and microcurrent electrical therapy (MET) for pain. Available in multiple product variants including Alpha-Stim M and Alpha-Stim AID.
• Pulvinar Neuro

Products and services

• Alpha-Stim M Non-invasive medical device combining cranial electrotherapy stimulation (CES) and microcurrent electrical therapy (MET), FDA-cleared for treatment of pain, anxiety, and insomnia. Delivers a patented waveform via mild microcurrents using earclip electrodes and handheld probes for pain treatment.
• Alpha-Stim AID Non-invasive cranial electrotherapy stimulation (CES) device FDA-cleared for anxiety and insomnia. Provides drug-free treatment through mild electrical currents delivered via earclip electrodes.
• AS-Trode Silver Electrode Pads Consumable silver electrode pads for use with the Alpha-Stim M device to treat acute, chronic, and post-traumatic pain.
• XCSITE-RD Non-invasive brain stimulation research solution developed by Pulvinar Neuro, capable of delivering high-powered tACS, tDCS, and custom waveform stimulation. Designed for researchers, portable and easy to use, includes double-blind capable software with active-sham and multiple study management features.
• XCSITE (Investigational) Investigational non-invasive brain stimulation device that uses EEG to detect brain waves and emits weak electrical currents to alleviate depression symptoms. Developed by Pulvinar Neuro and Dr. Flavio Frohlich at UNC, showing promising results in clinical trials for Major Depressive Disorder treatment.
• Closed-Loop tACS Device Investigational device with FDA Breakthrough Device Designation for personalized brain stimulation using real-time EEG measurements to deliver tailored transcranial alternating current stimulation for rapid relief of Major Depressive Disorder symptoms.

Quantifiable outcome

• 80% of patients with MDD were free of clinical depression symptoms two weeks post-treatment after five daily sessions with closed-loop tACS
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• AcuityMDcoreTechnology or Integration · 11 November 2025EPI partnered with AcuityMD to expand access to Alpha-Stim through their AI intelligence platform. The partnership enhanced outreach to VA and community care providers, leading to increased market penetration and sales productivity. AcuityMD aggregated VA data and community care facility information, enabling EPI to identify high-volume target physicians and prioritize outreach efficiently.
• Pulvinar NeurocoreStrategic or Co-development Partner · 1 March 2022EPI acquired Pulvinar Neuro in March 2022. Pulvinar is now a wholly-owned subsidiary of EPI specializing in non-invasive brain stimulation therapeutics. The acquisition accelerated development of patented closed-loop and novel neuromodulating brain stimulation solutions for clinical treatment of mental health disorders.
• University of North Carolina - Chapel HillcoreStrategic or Co-development PartnerResearchers from UNC Department of Psychiatry collaborated with EPI on breakthrough clinical trial published in American Journal of Psychiatry. Trial demonstrated 80% remission rate in MDD patients using closed-loop tACS technology. Dr. Flavio Frohlich (Associate Professor of Psychiatry, Director of Carolina Center for Neurostimulation) chairs EPI's Scientific Advisory Board.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Neuronetics: Neuronetics markets NeuroStar TMS, a transcranial magnetic stimulation system for major depressive disorder, competing directly with EPI's neuromodulation devices for the same prescriber and patient population in MDD treatment.
• BrainsWay: BrainsWay develops deep TMS systems for depression, OCD, and other psychiatric and neurological conditions, making it a direct competitor in non-invasive neuromodulation therapeutics for mental health.
• Fisher Wallace: Fisher Wallace manufactures wearable CES devices for depression, anxiety, and insomnia, directly overlapping with EPI's Alpha-Stim cranial electrotherapy stimulation product category and target patient base.
• electroCore: electroCore produces non-invasive vagus nerve stimulation (nVNS) devices for migraine, cluster headache, and other indications, competing with Alpha-Stim in the non-invasive, non-pharmaceutical neuromodulation category.
• Soterix Medical: Soterix Medical is a leader in tDCS, tACS, and HD-tES research and clinical devices, overlapping with EPI/Pulvinar's research-oriented XCSITE-RD platform and broader non-invasive brain stimulation technology.

Emerging players

• Flow Neuroscience: Flow Neuroscience offers a home-use tDCS headset for depression treatment, overlapping with EPI's investigational closed-loop tACS product and competing for at-home neuromodulation consumers.

Broad incumbents

• Magstim: Magstim is an established manufacturer of transcranial magnetic stimulation systems used in research and clinical depression treatment, competing in the broader non-invasive neuromodulation space.
• Abbott (formerly St. Jude Medical): Abbott manufactures implantable neuromodulation devices (spinal cord and deep brain stimulation) across pain and movement disorders, operating broadly in the neuromodulation medical device industry as an established incumbent.
• Boston Scientific: Boston Scientific's neuromodulation division produces spinal cord and deep brain stimulation systems for chronic pain and neurological conditions, representing a large incumbent competitor in the broader neuromodulation therapeutics market.

Regional players

• NeuroPace: NeuroPace markets the RNS System, an implantable closed-loop neurostimulation device for refractory epilepsy, sharing the closed-loop brain stimulation paradigm with EPI's Pulvinar Neuro subsidiary, though focused on epilepsy rather than MDD.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Electromedical Products International